BIOMEDICINE & PHARMACOTHERAPY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=3小时前, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2211149, encodeId=66d8221114902, content=今年已经降到6.9了，晕死，好歹7.0都行啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Sat Jun 22 14:45:09 CST 2024, time=2024-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2212739, encodeId=39512212e39e1, content=偏重的研究方向：肿瘤 经验分享：四天了还是今天还是Submitted to journal 上个杂志这时候早给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7a28287300, createdName=ms4000000395720318, createdTime=Tue Jul 02 12:23:14 CST 2024, time=昨天, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166373, encodeId=9cbe21663e32c, content=偏重的研究方向：肿瘤;综述 经验分享：从submit到with editor 花了21天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b42e5711504, createdName=ms1000000865900030, createdTime=Thu Nov 02 22:12:08 CST 2023, time=2023-11-02, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2211839, encodeId=cd5c221183967, content=记录一下，6月 26投稿，编辑要求提交wb原始条带, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=一投就中6, createdTime=Wed Jun 26 21:56:03 CST 2024, time=2024-06-26, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0 经验分享：3.12 投稿 3.15 with editor 3.18 under review 3.24 revise 3.29 返稿 4.7 revise 4.13 返稿 4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212314, encodeId=9297221231428, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;细胞死亡 经验分享：细胞死亡领域的热门方向综述文章： 3月6日(星期三) 被Pharmacological Research拒稿，直接改格式转投稿Biomedicine & Pharmacotherapy 4月18日(星期四)返回审稿意见 5月16日(星期四) 修改稿提交 6月4日(星期二) 接收 I am pleased to inform you that your manuscript has been accepted for publication.   6月5日(星期三) 校稿We are pleased to inform you that the proof for your upcoming publication 校稿三天后在线出版。 6月14日(星期五) 缴出版费3060欧元（约2.4w元）Please complete the Rights & Access form ；pay APC, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/r9tbp1yt51gZvE1JaeHJk18FrjgKxTl1Y9FrqZibmwpuIicKlPGXbCSjHoNW6U4zo5iasJ8TSFN2prGBDLia9NGn6w/132, createdBy=d62e2511453, createdName=zhaowumanus, createdTime=Sat Jun 29 10:33:30 CST 2024, time=2024-06-29, status=1, ipAttribution=湖北省)]

3小时前 ms4000000529451557 来自河南省

偏重的研究方向：肿瘤
经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=3小时前, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2211149, encodeId=66d8221114902, content=今年已经降到6.9了，晕死，好歹7.0都行啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Sat Jun 22 14:45:09 CST 2024, time=2024-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2212739, encodeId=39512212e39e1, content=偏重的研究方向：肿瘤 经验分享：四天了还是今天还是Submitted to journal 上个杂志这时候早给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7a28287300, createdName=ms4000000395720318, createdTime=Tue Jul 02 12:23:14 CST 2024, time=昨天, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166373, encodeId=9cbe21663e32c, content=偏重的研究方向：肿瘤;综述 经验分享：从submit到with editor 花了21天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b42e5711504, createdName=ms1000000865900030, createdTime=Thu Nov 02 22:12:08 CST 2023, time=2023-11-02, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2211839, encodeId=cd5c221183967, content=记录一下，6月 26投稿，编辑要求提交wb原始条带, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=一投就中6, createdTime=Wed Jun 26 21:56:03 CST 2024, time=2024-06-26, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0 经验分享：3.12 投稿 3.15 with editor 3.18 under review 3.24 revise 3.29 返稿 4.7 revise 4.13 返稿 4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212314, encodeId=9297221231428, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;细胞死亡 经验分享：细胞死亡领域的热门方向综述文章： 3月6日(星期三) 被Pharmacological Research拒稿，直接改格式转投稿Biomedicine & Pharmacotherapy 4月18日(星期四)返回审稿意见 5月16日(星期四) 修改稿提交 6月4日(星期二) 接收 I am pleased to inform you that your manuscript has been accepted for publication.   6月5日(星期三) 校稿We are pleased to inform you that the proof for your upcoming publication 校稿三天后在线出版。 6月14日(星期五) 缴出版费3060欧元（约2.4w元）Please complete the Rights & Access form ；pay APC, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/r9tbp1yt51gZvE1JaeHJk18FrjgKxTl1Y9FrqZibmwpuIicKlPGXbCSjHoNW6U4zo5iasJ8TSFN2prGBDLia9NGn6w/132, createdBy=d62e2511453, createdName=zhaowumanus, createdTime=Sat Jun 29 10:33:30 CST 2024, time=2024-06-29, status=1, ipAttribution=湖北省)]

2024-06-22 ms7000000856963905 来自四川省

今年已经降到6.9了，晕死，好歹7.0都行啊。。。。。

7 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=3小时前, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2211149, encodeId=66d8221114902, content=今年已经降到6.9了，晕死，好歹7.0都行啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Sat Jun 22 14:45:09 CST 2024, time=2024-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2212739, encodeId=39512212e39e1, content=偏重的研究方向：肿瘤 经验分享：四天了还是今天还是Submitted to journal 上个杂志这时候早给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7a28287300, createdName=ms4000000395720318, createdTime=Tue Jul 02 12:23:14 CST 2024, time=昨天, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166373, encodeId=9cbe21663e32c, content=偏重的研究方向：肿瘤;综述 经验分享：从submit到with editor 花了21天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b42e5711504, createdName=ms1000000865900030, createdTime=Thu Nov 02 22:12:08 CST 2023, time=2023-11-02, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2211839, encodeId=cd5c221183967, content=记录一下，6月 26投稿，编辑要求提交wb原始条带, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=一投就中6, createdTime=Wed Jun 26 21:56:03 CST 2024, time=2024-06-26, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0 经验分享：3.12 投稿 3.15 with editor 3.18 under review 3.24 revise 3.29 返稿 4.7 revise 4.13 返稿 4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212314, encodeId=9297221231428, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;细胞死亡 经验分享：细胞死亡领域的热门方向综述文章： 3月6日(星期三) 被Pharmacological Research拒稿，直接改格式转投稿Biomedicine & Pharmacotherapy 4月18日(星期四)返回审稿意见 5月16日(星期四) 修改稿提交 6月4日(星期二) 接收 I am pleased to inform you that your manuscript has been accepted for publication.   6月5日(星期三) 校稿We are pleased to inform you that the proof for your upcoming publication 校稿三天后在线出版。 6月14日(星期五) 缴出版费3060欧元（约2.4w元）Please complete the Rights & Access form ；pay APC, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/r9tbp1yt51gZvE1JaeHJk18FrjgKxTl1Y9FrqZibmwpuIicKlPGXbCSjHoNW6U4zo5iasJ8TSFN2prGBDLia9NGn6w/132, createdBy=d62e2511453, createdName=zhaowumanus, createdTime=Sat Jun 29 10:33:30 CST 2024, time=2024-06-29, status=1, ipAttribution=湖北省)]

昨天 ms4000000395720318 来自北京

偏重的研究方向：肿瘤
经验分享：四天了还是今天还是Submitted to journal 上个杂志这时候早给我拒了

1 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=3小时前, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2211149, encodeId=66d8221114902, content=今年已经降到6.9了，晕死，好歹7.0都行啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Sat Jun 22 14:45:09 CST 2024, time=2024-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2212739, encodeId=39512212e39e1, content=偏重的研究方向：肿瘤 经验分享：四天了还是今天还是Submitted to journal 上个杂志这时候早给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7a28287300, createdName=ms4000000395720318, createdTime=Tue Jul 02 12:23:14 CST 2024, time=昨天, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166373, encodeId=9cbe21663e32c, content=偏重的研究方向：肿瘤;综述 经验分享：从submit到with editor 花了21天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b42e5711504, createdName=ms1000000865900030, createdTime=Thu Nov 02 22:12:08 CST 2023, time=2023-11-02, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2211839, encodeId=cd5c221183967, content=记录一下，6月 26投稿，编辑要求提交wb原始条带, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=一投就中6, createdTime=Wed Jun 26 21:56:03 CST 2024, time=2024-06-26, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0 经验分享：3.12 投稿 3.15 with editor 3.18 under review 3.24 revise 3.29 返稿 4.7 revise 4.13 返稿 4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212314, encodeId=9297221231428, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;细胞死亡 经验分享：细胞死亡领域的热门方向综述文章： 3月6日(星期三) 被Pharmacological Research拒稿，直接改格式转投稿Biomedicine & Pharmacotherapy 4月18日(星期四)返回审稿意见 5月16日(星期四) 修改稿提交 6月4日(星期二) 接收 I am pleased to inform you that your manuscript has been accepted for publication.   6月5日(星期三) 校稿We are pleased to inform you that the proof for your upcoming publication 校稿三天后在线出版。 6月14日(星期五) 缴出版费3060欧元（约2.4w元）Please complete the Rights & Access form ；pay APC, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/r9tbp1yt51gZvE1JaeHJk18FrjgKxTl1Y9FrqZibmwpuIicKlPGXbCSjHoNW6U4zo5iasJ8TSFN2prGBDLia9NGn6w/132, createdBy=d62e2511453, createdName=zhaowumanus, createdTime=Sat Jun 29 10:33:30 CST 2024, time=2024-06-29, status=1, ipAttribution=湖北省)]

2023-11-02 ms1000000865900030 来自贵州省

偏重的研究方向：肿瘤;综述
经验分享：从submit到with editor 花了21天

47 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=3小时前, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2211149, encodeId=66d8221114902, content=今年已经降到6.9了，晕死，好歹7.0都行啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Sat Jun 22 14:45:09 CST 2024, time=2024-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2212739, encodeId=39512212e39e1, content=偏重的研究方向：肿瘤 经验分享：四天了还是今天还是Submitted to journal 上个杂志这时候早给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7a28287300, createdName=ms4000000395720318, createdTime=Tue Jul 02 12:23:14 CST 2024, time=昨天, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166373, encodeId=9cbe21663e32c, content=偏重的研究方向：肿瘤;综述 经验分享：从submit到with editor 花了21天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b42e5711504, createdName=ms1000000865900030, createdTime=Thu Nov 02 22:12:08 CST 2023, time=2023-11-02, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2211839, encodeId=cd5c221183967, content=记录一下，6月 26投稿，编辑要求提交wb原始条带, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=一投就中6, createdTime=Wed Jun 26 21:56:03 CST 2024, time=2024-06-26, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0 经验分享：3.12 投稿 3.15 with editor 3.18 under review 3.24 revise 3.29 返稿 4.7 revise 4.13 返稿 4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212314, encodeId=9297221231428, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;细胞死亡 经验分享：细胞死亡领域的热门方向综述文章： 3月6日(星期三) 被Pharmacological Research拒稿，直接改格式转投稿Biomedicine & Pharmacotherapy 4月18日(星期四)返回审稿意见 5月16日(星期四) 修改稿提交 6月4日(星期二) 接收 I am pleased to inform you that your manuscript has been accepted for publication.   6月5日(星期三) 校稿We are pleased to inform you that the proof for your upcoming publication 校稿三天后在线出版。 6月14日(星期五) 缴出版费3060欧元（约2.4w元）Please complete the Rights & Access form ；pay APC, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/r9tbp1yt51gZvE1JaeHJk18FrjgKxTl1Y9FrqZibmwpuIicKlPGXbCSjHoNW6U4zo5iasJ8TSFN2prGBDLia9NGn6w/132, createdBy=d62e2511453, createdName=zhaowumanus, createdTime=Sat Jun 29 10:33:30 CST 2024, time=2024-06-29, status=1, ipAttribution=湖北省)]

2023-07-31 ms6000001702952186 来自湖南省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：分子生物学;肿瘤;综述
经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运

51 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=3小时前, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2211149, encodeId=66d8221114902, content=今年已经降到6.9了，晕死，好歹7.0都行啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Sat Jun 22 14:45:09 CST 2024, time=2024-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2212739, encodeId=39512212e39e1, content=偏重的研究方向：肿瘤 经验分享：四天了还是今天还是Submitted to journal 上个杂志这时候早给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7a28287300, createdName=ms4000000395720318, createdTime=Tue Jul 02 12:23:14 CST 2024, time=昨天, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166373, encodeId=9cbe21663e32c, content=偏重的研究方向：肿瘤;综述 经验分享：从submit到with editor 花了21天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b42e5711504, createdName=ms1000000865900030, createdTime=Thu Nov 02 22:12:08 CST 2023, time=2023-11-02, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2211839, encodeId=cd5c221183967, content=记录一下，6月 26投稿，编辑要求提交wb原始条带, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=一投就中6, createdTime=Wed Jun 26 21:56:03 CST 2024, time=2024-06-26, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0 经验分享：3.12 投稿 3.15 with editor 3.18 under review 3.24 revise 3.29 返稿 4.7 revise 4.13 返稿 4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212314, encodeId=9297221231428, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;细胞死亡 经验分享：细胞死亡领域的热门方向综述文章： 3月6日(星期三) 被Pharmacological Research拒稿，直接改格式转投稿Biomedicine & Pharmacotherapy 4月18日(星期四)返回审稿意见 5月16日(星期四) 修改稿提交 6月4日(星期二) 接收 I am pleased to inform you that your manuscript has been accepted for publication.   6月5日(星期三) 校稿We are pleased to inform you that the proof for your upcoming publication 校稿三天后在线出版。 6月14日(星期五) 缴出版费3060欧元（约2.4w元）Please complete the Rights & Access form ；pay APC, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/r9tbp1yt51gZvE1JaeHJk18FrjgKxTl1Y9FrqZibmwpuIicKlPGXbCSjHoNW6U4zo5iasJ8TSFN2prGBDLia9NGn6w/132, createdBy=d62e2511453, createdName=zhaowumanus, createdTime=Sat Jun 29 10:33:30 CST 2024, time=2024-06-29, status=1, ipAttribution=湖北省)]

2024-06-26 一投就中6 来自辽宁省

记录一下，6月 26投稿，编辑要求提交wb原始条带

5 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=3小时前, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2211149, encodeId=66d8221114902, content=今年已经降到6.9了，晕死，好歹7.0都行啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Sat Jun 22 14:45:09 CST 2024, time=2024-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2212739, encodeId=39512212e39e1, content=偏重的研究方向：肿瘤 经验分享：四天了还是今天还是Submitted to journal 上个杂志这时候早给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7a28287300, createdName=ms4000000395720318, createdTime=Tue Jul 02 12:23:14 CST 2024, time=昨天, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166373, encodeId=9cbe21663e32c, content=偏重的研究方向：肿瘤;综述 经验分享：从submit到with editor 花了21天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b42e5711504, createdName=ms1000000865900030, createdTime=Thu Nov 02 22:12:08 CST 2023, time=2023-11-02, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2211839, encodeId=cd5c221183967, content=记录一下，6月 26投稿，编辑要求提交wb原始条带, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=一投就中6, createdTime=Wed Jun 26 21:56:03 CST 2024, time=2024-06-26, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0 经验分享：3.12 投稿 3.15 with editor 3.18 under review 3.24 revise 3.29 返稿 4.7 revise 4.13 返稿 4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212314, encodeId=9297221231428, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;细胞死亡 经验分享：细胞死亡领域的热门方向综述文章： 3月6日(星期三) 被Pharmacological Research拒稿，直接改格式转投稿Biomedicine & Pharmacotherapy 4月18日(星期四)返回审稿意见 5月16日(星期四) 修改稿提交 6月4日(星期二) 接收 I am pleased to inform you that your manuscript has been accepted for publication.   6月5日(星期三) 校稿We are pleased to inform you that the proof for your upcoming publication 校稿三天后在线出版。 6月14日(星期五) 缴出版费3060欧元（约2.4w元）Please complete the Rights & Access form ；pay APC, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/r9tbp1yt51gZvE1JaeHJk18FrjgKxTl1Y9FrqZibmwpuIicKlPGXbCSjHoNW6U4zo5iasJ8TSFN2prGBDLia9NGn6w/132, createdBy=d62e2511453, createdName=zhaowumanus, createdTime=Sat Jun 29 10:33:30 CST 2024, time=2024-06-29, status=1, ipAttribution=湖北省)]

2023-12-15 147ddcd3m55暂无昵称来自北京

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;综述
经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。

32 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=3小时前, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2211149, encodeId=66d8221114902, content=今年已经降到6.9了，晕死，好歹7.0都行啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Sat Jun 22 14:45:09 CST 2024, time=2024-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2212739, encodeId=39512212e39e1, content=偏重的研究方向：肿瘤 经验分享：四天了还是今天还是Submitted to journal 上个杂志这时候早给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7a28287300, createdName=ms4000000395720318, createdTime=Tue Jul 02 12:23:14 CST 2024, time=昨天, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166373, encodeId=9cbe21663e32c, content=偏重的研究方向：肿瘤;综述 经验分享：从submit到with editor 花了21天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b42e5711504, createdName=ms1000000865900030, createdTime=Thu Nov 02 22:12:08 CST 2023, time=2023-11-02, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2211839, encodeId=cd5c221183967, content=记录一下，6月 26投稿，编辑要求提交wb原始条带, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=一投就中6, createdTime=Wed Jun 26 21:56:03 CST 2024, time=2024-06-26, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0 经验分享：3.12 投稿 3.15 with editor 3.18 under review 3.24 revise 3.29 返稿 4.7 revise 4.13 返稿 4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212314, encodeId=9297221231428, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;细胞死亡 经验分享：细胞死亡领域的热门方向综述文章： 3月6日(星期三) 被Pharmacological Research拒稿，直接改格式转投稿Biomedicine & Pharmacotherapy 4月18日(星期四)返回审稿意见 5月16日(星期四) 修改稿提交 6月4日(星期二) 接收 I am pleased to inform you that your manuscript has been accepted for publication.   6月5日(星期三) 校稿We are pleased to inform you that the proof for your upcoming publication 校稿三天后在线出版。 6月14日(星期五) 缴出版费3060欧元（约2.4w元）Please complete the Rights & Access form ；pay APC, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/r9tbp1yt51gZvE1JaeHJk18FrjgKxTl1Y9FrqZibmwpuIicKlPGXbCSjHoNW6U4zo5iasJ8TSFN2prGBDLia9NGn6w/132, createdBy=d62e2511453, createdName=zhaowumanus, createdTime=Sat Jun 29 10:33:30 CST 2024, time=2024-06-29, status=1, ipAttribution=湖北省)]

2022-04-18 奶油

审稿速度:2.0
经验分享：3.12 投稿
3.15 with editor
3.18 under review
3.24 revise
3.29 返稿
4.7 revise
4.13 返稿
4.17 accept

202 44

展开44条回复

[GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=3小时前, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2211149, encodeId=66d8221114902, content=今年已经降到6.9了，晕死，好歹7.0都行啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Sat Jun 22 14:45:09 CST 2024, time=2024-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2212739, encodeId=39512212e39e1, content=偏重的研究方向：肿瘤 经验分享：四天了还是今天还是Submitted to journal 上个杂志这时候早给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7a28287300, createdName=ms4000000395720318, createdTime=Tue Jul 02 12:23:14 CST 2024, time=昨天, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166373, encodeId=9cbe21663e32c, content=偏重的研究方向：肿瘤;综述 经验分享：从submit到with editor 花了21天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b42e5711504, createdName=ms1000000865900030, createdTime=Thu Nov 02 22:12:08 CST 2023, time=2023-11-02, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2211839, encodeId=cd5c221183967, content=记录一下，6月 26投稿，编辑要求提交wb原始条带, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=一投就中6, createdTime=Wed Jun 26 21:56:03 CST 2024, time=2024-06-26, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0 经验分享：3.12 投稿 3.15 with editor 3.18 under review 3.24 revise 3.29 返稿 4.7 revise 4.13 返稿 4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212314, encodeId=9297221231428, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;细胞死亡 经验分享：细胞死亡领域的热门方向综述文章： 3月6日(星期三) 被Pharmacological Research拒稿，直接改格式转投稿Biomedicine & Pharmacotherapy 4月18日(星期四)返回审稿意见 5月16日(星期四) 修改稿提交 6月4日(星期二) 接收 I am pleased to inform you that your manuscript has been accepted for publication.   6月5日(星期三) 校稿We are pleased to inform you that the proof for your upcoming publication 校稿三天后在线出版。 6月14日(星期五) 缴出版费3060欧元（约2.4w元）Please complete the Rights & Access form ；pay APC, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/r9tbp1yt51gZvE1JaeHJk18FrjgKxTl1Y9FrqZibmwpuIicKlPGXbCSjHoNW6U4zo5iasJ8TSFN2prGBDLia9NGn6w/132, createdBy=d62e2511453, createdName=zhaowumanus, createdTime=Sat Jun 29 10:33:30 CST 2024, time=2024-06-29, status=1, ipAttribution=湖北省)]

2024-06-28 ms1000000212761733

记录一下
6月15号投稿，6月28号还是Submitted to Journal

5 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=3小时前, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2211149, encodeId=66d8221114902, content=今年已经降到6.9了，晕死，好歹7.0都行啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Sat Jun 22 14:45:09 CST 2024, time=2024-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2212739, encodeId=39512212e39e1, content=偏重的研究方向：肿瘤 经验分享：四天了还是今天还是Submitted to journal 上个杂志这时候早给我拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7a28287300, createdName=ms4000000395720318, createdTime=Tue Jul 02 12:23:14 CST 2024, time=昨天, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166373, encodeId=9cbe21663e32c, content=偏重的研究方向：肿瘤;综述 经验分享：从submit到with editor 花了21天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b42e5711504, createdName=ms1000000865900030, createdTime=Thu Nov 02 22:12:08 CST 2023, time=2023-11-02, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2211839, encodeId=cd5c221183967, content=记录一下，6月 26投稿，编辑要求提交wb原始条带, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=一投就中6, createdTime=Wed Jun 26 21:56:03 CST 2024, time=2024-06-26, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0 经验分享：3.12 投稿 3.15 with editor 3.18 under review 3.24 revise 3.29 返稿 4.7 revise 4.13 返稿 4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212314, encodeId=9297221231428, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;细胞死亡 经验分享：细胞死亡领域的热门方向综述文章： 3月6日(星期三) 被Pharmacological Research拒稿，直接改格式转投稿Biomedicine & Pharmacotherapy 4月18日(星期四)返回审稿意见 5月16日(星期四) 修改稿提交 6月4日(星期二) 接收 I am pleased to inform you that your manuscript has been accepted for publication.   6月5日(星期三) 校稿We are pleased to inform you that the proof for your upcoming publication 校稿三天后在线出版。 6月14日(星期五) 缴出版费3060欧元（约2.4w元）Please complete the Rights & Access form ；pay APC, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/r9tbp1yt51gZvE1JaeHJk18FrjgKxTl1Y9FrqZibmwpuIicKlPGXbCSjHoNW6U4zo5iasJ8TSFN2prGBDLia9NGn6w/132, createdBy=d62e2511453, createdName=zhaowumanus, createdTime=Sat Jun 29 10:33:30 CST 2024, time=2024-06-29, status=1, ipAttribution=湖北省)]

2024-06-29 zhaowumanus 来自湖北省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：分子生物学;细胞死亡
经验分享：细胞死亡领域的热门方向综述文章：
3月6日(星期三) 被Pharmacological Research拒稿，直接改格式转投稿Biomedicine & Pharmacotherapy
4月18日(星期四)返回审稿意见
5月16日(星期四) 修改稿提交
6月4日(星期二) 接收 I am pleased to inform you that your manuscript has been accepted for publication.  
6月5日(星期三) 校稿We are pleased to inform you that the proof for your upcoming publication
校稿三天后在线出版。
6月14日(星期五) 缴出版费3060欧元（约2.4w元）Please complete the Rights & Access form ；pay APC,

0 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务